- Health Spotlight's Microscopic Polyangiitis Insights
- Posts
- Weekly Spotlight - 12.12.24
Weekly Spotlight - 12.12.24
Low-Dose Steroids in Vasculitis: Risks and Real-World Insights
Liam Ball
December 12, 2024 • Estimated Reading Time: 3 minutes
Community |
Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured. |
The study highlights concerns with reduced-dose glucocorticoids in ANCA-associated vasculitis, showing increased risks of relapse and disease progression, especially in patients on rituximab or with high creatinine levels. While not affecting mortality or severe infections, careful monitoring is advised for these vulnerable groups.
Alaska Native and American Indian populations show higher rates of ANCA-associated vasculitis compared to white populations. This study highlights the need for awareness among rheumatologists about these elevated rates and the younger age of onset, emphasising the importance of tailored healthcare for these communities.
Polyarteriitis nodosa (PAN) is a rare disease in Europe, affecting 31 per million. The GLOBAL-PAN study examined demographics, symptoms, progression, and survival of patients. This research offers hope by enhancing understanding and potentially improving outcomes for those affected by this challenging condition.
Health Spotlight’s Microscopic Polyangiitis is a Contentive publication in the Healthcare division